The nomination of the prospective clinical candidate is the key milestone for any drug development program. It reflects the culmination of the challenging discovery work, intense scientific exploration, frustrating setbacks and great leaps forward. It also signals the initiation of one of the high-stakes phases of development: early Chemistry, Manufacturing, and Controls (CMC) getting the compound from the test tube to the clinic.
This transition often begins with just milligrams of material in hand. Although sufficient to demonstrate biological proof of concept and a drug-like profile, it is seldom enough to support pre-clinical development. Material requirements increase quickly. Within weeks or months, chemistry teams are expected to produce tens to hundreds of grams to support such critical preclinical activities as dose range-finding toxicology, GLP toxicology studies, formulation development, extended efficacy models, and solid form identification.
This is the point where scientific promise must be translated into a reliable technical package. The decisions made during early CMC will shape the trajectory and timeline of the entire program.
Is the Discovery Route Enough?
One of the most important early challenges is whether the existing discovery synthesis route is suitable for scale-up. Discovery routes are typically optimized for speed and flexibility at very small scale. They may rely on costly reagents, non-scalable reaction conditions, or purification strategies that become inefficient, unsafe, or impractical at gram or multi-gram scale.
Before committing to larger production campaigns, teams must evaluate route robustness through a development lens. This includes assessing reagent availability, impurity formation and control, yield consistency, process safety, and overall scalability. These considerations align closely with principles outlined in ICH Q11, which emphasizes building process understanding and control strategies early in drug substance development to support both clinical supply and regulatory expectations.
In some cases, modest optimization of the discovery route can be sufficient. In others, more significant re-engineering is required to ensure the process can support preclinical studies and remain viable as the program progresses toward clinical manufacturing. Significant changes in development route can alter the compound profile, affect the regulatory toxicology and impact the clinical formulation profile.
Building an Early Development Supply Chain
Scaling chemistry is only one part of the transition from discovery to development. Equally important is the rapid construction of a fit-for-purpose preclinical supply chain that balances speed, cost, quality, and regulatory demands.
This transition process involves multiple parallel workstreams. Raw materials and advanced intermediates must be sourced from reliable suppliers. Synthetic routes are refined to improve reproducibility and robustness. Teams define appropriate transition points between non-GMP and GMP manufacture, ensuring that toxicology and IND-enabling studies are supported by material that meets regulatory expectations.
Vendor selection is a critical element. Choosing the right partners for drug substance and drug product manufacturing requires careful evaluation of technical capability, capacity, quality systems, and regulatory track record. These decisions are frequently made under demanding timelines, yet they have lasting implications for IND readiness and clinical progression. A good match between vendors and the development team is paramount to success.
Throughout this phase, early alignment with regulatory guidance is essential. FDA CMC guidance for IND-enabling programs underscores the importance of clear documentation, justified manufacturing strategies, and thoughtful planning around material attributes and control approaches.
De-Risking the Path to IND
Early CMC is fundamentally about risk management. The goal is not to over-engineer processes, but to make informed, strategic decisions that reduce the likelihood of delays, rework, or regulatory questions later. Programs that navigate this phase successfully anticipate future needs, integrate CMC strategy with overall development goals, and maintain flexibility as data evolves. Experience and access to a breadth subject expertise are essential to move through this phase as smoothly as possible.
Strong technical insight, clear communication and good planning all contribute to smoother IND submissions and more confident regulatory interactions.
How Syner-G Can Help
Syner-G specializes in guiding emerging programs through the critical transition from discovery to development. With deep CMC expertise and hands-on experience across early-stage programs, our team helps clients evaluate discovery routes, design scalable processes, and build tailored preclinical supply chains.
Extensive experience in scale-up and regulatory CMC development combined with a broad network of trusted development and manufacturing partners, Syner-G supports drug substance and drug product strategies that are right-sized for early development while remaining aligned with long-term clinical and regulatory goals. Our focus is on delivering quality material on time, reducing risk, and positioning programs for successful IND submission.
Whether you are starting with milligrams or preparing to scale to hundreds of grams, Syner-G provides the strategic insight and technical execution needed to move forward with confidence.
Let’s talk about how Syner-G can support your early development journey.
